RVU.WAR Ryvu Therapeutics SA

Healthcare Biotechnology Warsaw Stock Exchange
17.80 PLN
Close of Oct 29, 2026
13.76 29.90
Market cap
PLN 412M
P/E
-
P/B
14.85x
ROE
-181.2%
Dividend yield
-
Fundamental score
0.9/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is RVU.WAR undervalued?

Graham number

The Graham number of Ryvu Therapeutics SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ryvu Therapeutics SA fundamental analysis

4 of 21 checks passed

ROE 0/2

Low return on equity (-181.2%), below 10%.

ROA 0/1

Return on assets (-28.2%) is below the industry median (-18.6%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share did not grow over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (9.2%) is above the industry median (2.6%).

Revenue Growth 2/2

Revenue grew 17.1% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 0/1

Current assets do not cover long-term liabilities.

Debt to Equity 0/2

High debt to equity (264.1%), above 100%.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Cash Runway 1/2

Cash covers 1.1 years of the current cash burn.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 0/1

Price to book (14.8x) is above the industry median (3.6x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Ryvu Therapeutics SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ryvu Therapeutics SA

Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It also develops Dapolsertib (SEL24/MEN1703), a dual PIM and FLT3 kin…

Full company profile